Hoffmann-la Roche Inc.

National Institutes of Health, a Component of the US Dept. of Health & Human Services

The United States of America As Represented by the Department of Health

Roche Glycart Ag

Pgxhealth, LLC

The United States of America As Represented by the Secretary of

The United States of America

F. Hoffmann-la Roche Ag

Ulrich Brinkmann

Guy Georges

Christian Klein

Ira H Pastan

Werner Scheuer

Eike Hoffmann

Joerg Thomas Regula

Anita Kavlie

Remko Griep

Juergen Michael Schanzer

Alexander Haas

Rebecca Croasdale

Olaf Mundigl

Klaus Kaluza

Byungkook Lee

Wolfgang Schaefer

Stefan Dengl

Klaus Mayer

Ekkehard Moessner

Sabine Imhof-Jung

Jan Olaf Stracke

Silke Metz

Michael Grote

Pablo Umana

Stefan Seeber

Hubert Kettenberger

Jens Niewoehner

Monika Baehner

Wilma Lau

Sun-Hee Jung

Markus Thomas

Erhard Kopetzki

Joerg Benz

George Vasmatzis

Claudio Sustmann

Mark C Willingham

Sebastian Dziadek

David Fitzgerald

Peter Bruenker

Birgit Bramlage

Georg Tiefenthaler

Curt Douglas Wolfgang

Masanori Onda

Gerhard Niederfellner

Harald Duerr

Matthias John

Johannes Auer

Kerstin Jahn-Hofmann

Ludger Ickenstein

Ronit Mazor

Katharina Wartha

Rebecca Croasdale-Wood

Remko Albert Griep

Daniela Maisel

Wilma Dormeyer

Lee Pai

Tobias Killian

Magnus Essand

Felix Bormann

Steffen Dickopf

Achim Gaertner

Simone Dill

Sven Hoffmeyer

Esther Mornhinweg

Anja Penger

Reimund Sprenger

Irmgard Thorey

Ludger Markus Ickenstein

Herein is reported a composition for the targeted delivery of large nucleic acids to the nucleus of a eukaryotic cell comprising non-covalent complexes of histones in form of assembled nucleosomes, a large nucleic acid, a hapten, and a bispecific binder that has a first binding specificity to the hapten and a second binding specificity to a cell-surface target present on the eukaryotic cell, wherein the histone and/or the nucleic acid is/are covalently bound/conjugated to the hapten, the histone and the large nucleic acid are associated (non-covalently) with each other/form a non-covalent complex, and the hapten and the bispecific binder are associated with each other/bound to each other by the first binding specificity of the bispecific binder.

Targeted intracellular delivery of large nucleic acids

Herein is reported a method for the generation of multispecific antibodies by a half-antibody exchange reaction between two 2/3-IgGs destabilized in one half by asymmetric perturbing mutations fostering the generation of correctly assemble full length bispecific antibodies. The method can be performed in the absence of reducing agents and does not require hinge region disulfide bonds in the starting 2/3-IgGs.

Method for generating multispecific antibodies from monospecific antibodies

Herein is reported a method for the generation of multispecific antibodies directly on the cell-surface at the site of action by a half-antibody exchange reaction between two 2/3-IgGs or two 2/3-BiFabs destabilized in one half by asymmetric perturbing mutations fostering the generation of correctly assembled full length bi- or multispecific antibodies. The method is performed in the absence hinge region disulfide bonds in the starting 2/3-IgGs or 2/3-BiFabs.

Method for in vivo generation of multispecific antibodies from monospecific antibodies

Herein is reported a conjugate comprising an antigen and an antibody that specifically binds to the antigen wherein a covalent bond is formed between the antigen and an amino acid residue in the CDR2 of the antibody, an antibody comprising a cysteine residue at amino acid position 53 (according to Kabat) in the heavy chain CDR2 and uses thereof.

Covalently linked antigen-antibody conjugates

The present invention relates to multispecific antibodies comprising at least three antigen binding sites wherein the third binding site is disulfide stabilized by introduction of cysteine, method for their production, pharmaceutical compositions containing said antibodies and uses thereof.

Multispecific antibodies

The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.

Trivalent, bispecific antibodies

The invention provides anti-BRDU antibodies and methods of using the same.

Anti-BRDU antibodies and methods of use

Herein is reported a bispecific antibody comprising a first binding specificity that specifically binds to a haptenylated payload and a second binding specificity that specifically binds to a blood brain barrier receptor.

Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles

The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.

Herein is reported a conjugate of a haptenylated polypeptide toxin and an anti-hapten antibody, wherein a disulfide bond is formed between a cysteine residue either before or after the lysine residue that is used for hapten-conjugation and a cysteine residue in the CDR2 of the antibody, whereby the CDR2 is determined according to Kabat.

Covalently linked polypeptide toxin-antibody conjugates

Herein is reported a conjugate comprising a helicar motif amino acid sequence containing compound and an antibody that specifically binds to the helicar motif amino acid sequence characterized by a covalent bond between the helicar motif amino acid sequence containing compound and an amino acid residue in the CDR2 of the anti-helicar antibody, whereby the CDR2 is determined according to Kabat.

Covalently linked helicar-anti-helicar antibody conjugates and uses thereof

The present invention relates to bispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific antibodies

Growing community of inventors

Weilheim, Germany

Ulrich Brinkmann